Cargando…

Adults With Congenital Heart Disease: Trends in Event-Free Survival Past Middle Age

The survival of children with congenital heart disease has increased substantially over the past decades, with 97% currently reaching adulthood. The total effect of advanced treatment on future mortality and morbidity in adult survivors with congenital heart disease (CHD) is less well described. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Dellborg, Mikael, Giang, Kok Wai, Eriksson, Peter, Liden, Hans, Fedchenko, Maria, Ahnfelt, Anders, Rosengren, Annika, Mandalenakis, Zacharias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022672/
https://www.ncbi.nlm.nih.gov/pubmed/36571845
http://dx.doi.org/10.1161/CIRCULATIONAHA.122.060834
_version_ 1784908771372302336
author Dellborg, Mikael
Giang, Kok Wai
Eriksson, Peter
Liden, Hans
Fedchenko, Maria
Ahnfelt, Anders
Rosengren, Annika
Mandalenakis, Zacharias
author_facet Dellborg, Mikael
Giang, Kok Wai
Eriksson, Peter
Liden, Hans
Fedchenko, Maria
Ahnfelt, Anders
Rosengren, Annika
Mandalenakis, Zacharias
author_sort Dellborg, Mikael
collection PubMed
description The survival of children with congenital heart disease has increased substantially over the past decades, with 97% currently reaching adulthood. The total effect of advanced treatment on future mortality and morbidity in adult survivors with congenital heart disease (CHD) is less well described. METHODS: We used data from the Swedish National Inpatient, Outpatient, and Cause of Death Register to identify patients with CHD who were born between 1950 and 1999 and were alive at 18 years of age. Ten controls identified from the Total Population Register were matched for year of birth and sex and with each patient with CHD. Follow-up was from 1968 and 18 years of age until death or at the end of the study (2017). Survival percentage with 95% CI for all-cause mortality were performed with Kaplan-Meier survival function. Cox proportional hazard regression models with hazard ratios (HRs) and 95% CI were used to estimate the risk of all-cause mortality. RESULTS: We included 37 278 patients with adult CHD (ACHD) and 412 799 controls. Mean follow-up was 19.2 years (±13.6). Altogether, 1937 patients with ACHD (5.2%) and 6690 controls (1.6%) died, a death rate of 2.73 per 1000 person-years and 0.84 per 1000 person years, respectively. Mortality was 3.2 times higher (95% CI, 3.0–3.4; P<0.001) among patients with ACHD compared with matched controls. Up to the maximum of 50 years of follow-up, >75% of patients with ACHD were still alive. Mortality was highest among patients with conotruncal defects (HR, 10.13 [95% CI, 8.78–11.69]), but also significantly higher for the more benign lesions, with the lowest risk in patients with atrial septal defects (HR, 1.36 [95% CI, 1.19–1.55]). At least 75% of patients with ACHD alive at 18 years of age lived past middle age and became sexagenerians. CONCLUSIONS: In this large, nationwide, register-based cohort study of patients with ACHD surviving to 18 years of age, the risk of mortality up to 68 years of age was >3 times higher compared with matched controls without ACHD. Despite this, at least 75% of patients with CHD alive at 18 years of age lived past middle age and became sexagenerians. A notable risk decline in the mortality for patients with ACHD was seen for those born after 1975.
format Online
Article
Text
id pubmed-10022672
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-100226722023-03-18 Adults With Congenital Heart Disease: Trends in Event-Free Survival Past Middle Age Dellborg, Mikael Giang, Kok Wai Eriksson, Peter Liden, Hans Fedchenko, Maria Ahnfelt, Anders Rosengren, Annika Mandalenakis, Zacharias Circulation Original Research Articles The survival of children with congenital heart disease has increased substantially over the past decades, with 97% currently reaching adulthood. The total effect of advanced treatment on future mortality and morbidity in adult survivors with congenital heart disease (CHD) is less well described. METHODS: We used data from the Swedish National Inpatient, Outpatient, and Cause of Death Register to identify patients with CHD who were born between 1950 and 1999 and were alive at 18 years of age. Ten controls identified from the Total Population Register were matched for year of birth and sex and with each patient with CHD. Follow-up was from 1968 and 18 years of age until death or at the end of the study (2017). Survival percentage with 95% CI for all-cause mortality were performed with Kaplan-Meier survival function. Cox proportional hazard regression models with hazard ratios (HRs) and 95% CI were used to estimate the risk of all-cause mortality. RESULTS: We included 37 278 patients with adult CHD (ACHD) and 412 799 controls. Mean follow-up was 19.2 years (±13.6). Altogether, 1937 patients with ACHD (5.2%) and 6690 controls (1.6%) died, a death rate of 2.73 per 1000 person-years and 0.84 per 1000 person years, respectively. Mortality was 3.2 times higher (95% CI, 3.0–3.4; P<0.001) among patients with ACHD compared with matched controls. Up to the maximum of 50 years of follow-up, >75% of patients with ACHD were still alive. Mortality was highest among patients with conotruncal defects (HR, 10.13 [95% CI, 8.78–11.69]), but also significantly higher for the more benign lesions, with the lowest risk in patients with atrial septal defects (HR, 1.36 [95% CI, 1.19–1.55]). At least 75% of patients with ACHD alive at 18 years of age lived past middle age and became sexagenerians. CONCLUSIONS: In this large, nationwide, register-based cohort study of patients with ACHD surviving to 18 years of age, the risk of mortality up to 68 years of age was >3 times higher compared with matched controls without ACHD. Despite this, at least 75% of patients with CHD alive at 18 years of age lived past middle age and became sexagenerians. A notable risk decline in the mortality for patients with ACHD was seen for those born after 1975. Lippincott Williams & Wilkins 2022-12-26 2023-03-21 /pmc/articles/PMC10022672/ /pubmed/36571845 http://dx.doi.org/10.1161/CIRCULATIONAHA.122.060834 Text en © 2022 The Authors. https://creativecommons.org/licenses/by-nc-nd/4.0/Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.
spellingShingle Original Research Articles
Dellborg, Mikael
Giang, Kok Wai
Eriksson, Peter
Liden, Hans
Fedchenko, Maria
Ahnfelt, Anders
Rosengren, Annika
Mandalenakis, Zacharias
Adults With Congenital Heart Disease: Trends in Event-Free Survival Past Middle Age
title Adults With Congenital Heart Disease: Trends in Event-Free Survival Past Middle Age
title_full Adults With Congenital Heart Disease: Trends in Event-Free Survival Past Middle Age
title_fullStr Adults With Congenital Heart Disease: Trends in Event-Free Survival Past Middle Age
title_full_unstemmed Adults With Congenital Heart Disease: Trends in Event-Free Survival Past Middle Age
title_short Adults With Congenital Heart Disease: Trends in Event-Free Survival Past Middle Age
title_sort adults with congenital heart disease: trends in event-free survival past middle age
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022672/
https://www.ncbi.nlm.nih.gov/pubmed/36571845
http://dx.doi.org/10.1161/CIRCULATIONAHA.122.060834
work_keys_str_mv AT dellborgmikael adultswithcongenitalheartdiseasetrendsineventfreesurvivalpastmiddleage
AT giangkokwai adultswithcongenitalheartdiseasetrendsineventfreesurvivalpastmiddleage
AT erikssonpeter adultswithcongenitalheartdiseasetrendsineventfreesurvivalpastmiddleage
AT lidenhans adultswithcongenitalheartdiseasetrendsineventfreesurvivalpastmiddleage
AT fedchenkomaria adultswithcongenitalheartdiseasetrendsineventfreesurvivalpastmiddleage
AT ahnfeltanders adultswithcongenitalheartdiseasetrendsineventfreesurvivalpastmiddleage
AT rosengrenannika adultswithcongenitalheartdiseasetrendsineventfreesurvivalpastmiddleage
AT mandalenakiszacharias adultswithcongenitalheartdiseasetrendsineventfreesurvivalpastmiddleage